Cancer clinical trials in the region Hauts-de-France

163 currently recruiting clinical trials
Region Hauts-de-France

Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized ALK None Systemic Treatment-Naive Surgery
Hoffmann-La Roche
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive
ALK EGFR
Bristol-Myers Squibb
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
Phase 3 Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic KRAS G12C PDL1 Negative (< 1%) None Systemic Treatment-Naive
Targeted therapy Immunotherapy Chemotherapy Targeted therapy Car-T Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille)
Amgen
Phase 3 Lung cancer
#NCT06119581
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C Systemic Treatment-Naive
BRAF EGFR HER2 MET NTRK-1/2/3 RET ROS-1 Immunotherapy Chemotherapy Targeted therapy
Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille)
Eli Lilly et compagnie
Phase 3 Bladder / Urinary Tract / Urethral cancer
#NCT06319820
Non-invasive bladder cancer Localized FGFR None 1 2 3 or more
Centre Hospitalier Universitaire de Lille - Institut Cœur Poumon (Lille)
Janssen